BrainXell Therapeutics

About BrainXell Therapeutics

BrainXell Therapeutics Global is committed to making a meaningful difference in the lives of patients with neurodegenerative diseases and neuro-injury. In pursuit of this goal, we translate advanced cellular ​​​​science into autologous iPSC-derived therapies designed to regenerate the human central nervous system (CNS). We’re putting the decade of iPSC experience gained at our legacy company, BrainXell, Inc., into our pipeline programs for devastating neurological diseases, starting with Parkinson’s disease (PD). Our lead program, BXT-110, is an autologous, iPSC-derived midbrain dopaminergic progenitor (mDAP) cell therapy in development for moderate-to-severe PD. We are advancing BXT-110 to clinical testing in the next 6-12 months.  BrainXell Therapeutics’ technology is rooted in the expertise and innovation of​ our Founder, Dr. Su-Chun Zhang, a global pioneer in stem cell neuroscience. ​     ​   For more information, visit www.brainxelltx.com.